| Association of a novel long non‐coding RNA in 8q24 with prostate cancer susceptibility S Chung, H Nakagawa, M Uemura, L Piao, K Ashikawa, N Hosono, ... Cancer science 102 (1), 245-252, 2011 | 386 | 2011 |
| Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population R Takata, S Akamatsu, M Kubo, A Takahashi, N Hosono, T Kawaguchi, ... Nature genetics 42 (9), 751-754, 2010 | 335 | 2010 |
| The placental gene PEG10 promotes progression of neuroendocrine prostate cancer S Akamatsu, AW Wyatt, D Lin, S Lysakowski, F Zhang, S Kim, C Tse, ... Cell reports 12 (6), 922-936, 2015 | 285 | 2015 |
| Clinical and molecular features of treatment‐related neuroendocrine prostate cancer S Akamatsu, T Inoue, O Ogawa, ME Gleave International Journal of Urology 25 (4), 345-351, 2018 | 153 | 2018 |
| Common variants at 11q12, 10q26 and 3p11. 2 are associated with prostate cancer susceptibility in Japanese S Akamatsu, R Takata, CA Haiman, A Takahashi, T Inoue, M Kubo, ... Nature genetics 44 (4), 426-429, 2012 | 126 | 2012 |
| Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications N Terada, S Akamatsu, T Kobayashi, T Inoue, O Ogawa, ES Antonarakis Therapeutic advances in medical oncology 9 (8), 565-573, 2017 | 83 | 2017 |
| Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer T Sumiyoshi, K Mizuno, T Yamasaki, Y Miyazaki, Y Makino, K Okasho, ... Scientific Reports 9 (1), 4030, 2019 | 70 | 2019 |
| Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy‐naïve castration‐resistant prostate cancer: The Kyoto‐Baltimore collaboration N Terada, BL Maughan, S Akamatsu, T Kobayashi, T Yamasaki, T Inoue, ... International Journal of Urology 24 (6), 441-448, 2017 | 69 | 2017 |
| Association of missense polymorphism in HSD3B1 with outcomes among men with prostate cancer treated with androgen-deprivation therapy or abiraterone M Shiota, S Narita, S Akamatsu, N Fujimoto, T Sumiyoshi, M Fujiwara, ... JAMA Network Open 2 (2), e190115-e190115, 2019 | 61 | 2019 |
| Primary signet-ring cell carcinoma of the urinary bladder S Akamatsu, A Takahashi, M Ito, K Ogura Urology 75 (3), 615-618, 2010 | 61 | 2010 |
| Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide K Ueda, A Tatsuguchi, N Saichi, A Toyama, K Tamura, M Furihata, ... Journal of proteome research 12 (10), 4497-4506, 2013 | 60 | 2013 |
| Development and validation of a novel prognostic model for predicting overall survival in treatment-naïve castration-sensitive metastatic prostate cancer S Akamatsu, M Kubota, R Uozumi, S Narita, M Takahashi, K Mitsuzuka, ... European urology oncology 2 (3), 320-328, 2019 | 56 | 2019 |
| IRX4 at 5p15 suppresses prostate cancer growth through the interaction with vitamin D receptor, conferring prostate cancer susceptibility H Ha Nguyen, R Takata, S Akamatsu, D Shigemizu, T Tsunoda, ... Human molecular genetics 21 (9), 2076-2085, 2012 | 56 | 2012 |
| 12 new susceptibility loci for prostate cancer identified by genome-wide association study in Japanese population R Takata, A Takahashi, M Fujita, Y Momozawa, EJ Saunders, H Yamada, ... Nature communications 10 (1), 4422, 2019 | 51 | 2019 |
| Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies Y Kita, A Hamada, R Saito, Y Teramoto, R Tanaka, K Takano, ... British Journal of Cancer 121 (12), 1027-1038, 2019 | 50 | 2019 |
| Prostate cancer genomics, biology, and risk assessment through genome‐wide association studies H Nakagawa, S Akamatsu, R Takata, A Takahashi, M Kubo, Y Nakamura Cancer science 103 (4), 607-613, 2012 | 46 | 2012 |
| A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression S Akamatsu, R Takata, K Ashikawa, N Hosono, N Kamatani, T Fujioka, ... Human molecular genetics 19 (21), 4265-4272, 2010 | 43 | 2010 |
| Androgen receptor mutations for precision medicine in prostate cancer M Shiota, S Akamatsu, S Tsukahara, S Nagakawa, T Matsumoto, M Eto Endocrine-related cancer 29 (10), R143-R155, 2022 | 41 | 2022 |
| Primary large cell neuroendocrine carcinoma of the urinary bladder S Akamatsu, S Kanamaru, M Ishihara, T Sano, A Soeda, K Hashimoto International journal of urology 15 (12), 1080-1083, 2008 | 41 | 2008 |
| Castration-resistant prostate cancer refractory to second-generation androgen receptor axis-targeted agents: opportunities and challenges Y Kita, T Goto, S Akamatsu, T Yamasaki, T Inoue, O Ogawa, T Kobayashi Cancers 10 (10), 345, 2018 | 40 | 2018 |
